Cost-effectiveness of strontium ranelate versus intravenous ibandronate in the treatment of postmenopausal women

Mickaël Hiligsmann; Audrey Neuprez; Sophie Scholtissen; Jean-Yves Reginster

Back

Cost-effectiveness of strontium ranelate versus intravenous ibandronate in the treatment of postmenopausal women

Conference proceeding

Peer reviewed

Cost-effectiveness of strontium ranelate versus intravenous ibandronate in the treatment of postmenopausal women

Mickaël Hiligsmann, Audrey Neuprez, Sophie Scholtissen and Jean-Yves Reginster

Osteoporosis International, 20 (S1), 130 (2009-03); 9th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthrithis, Athènes, Greece [GR], du 18 mars 2009 au 21 mars 2009

03/2009

Abstract

Business & economic sciences

Domaines particuliers de l’économie (santé, travail, transport...)

Human health sciences

Rheumatology

Rhumatologie

Sciences de la santé humaine

Sciences économiques & de gestion

Special economic topics (health, labor, transportation...)

Metrics

1 Record Views

Details

Title: Cost-effectiveness of strontium ranelate versus intravenous ibandronate in the treatment of postmenopausal women
Creators - without role: Mickaël Hiligsmann
Audrey Neuprez
Sophie Scholtissen
Jean-Yves Reginster
Conference: Osteoporosis International, 20 (S1), 130 (2009-03); 9th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthrithis, Athènes, Greece [GR], du 18 mars 2009 au 21 mars 2009
Publisher: Springer Science & Business Media B.V
Identifiers: 9951883008331
Academic Unit: King Saud University
Language: English
Resource Type: Conference proceeding